NCT04482270View on ClinicalTrials.gov

A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

March 22, 2021

Study Completion Date

March 22, 2021

Conditions

Hepatic ImpairmentHealthy Volunteers

Interventions

DRUG

fezolinetant

Oral

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

33765

Clinical Research of West Florida, Inc., Clearwater

72815

American Research Corporation, San Antonio

33014-361

Clinical Pharmacology of Miami, LLC, Miami

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT04482270 - A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function | Biotech Hunter | Biotech Hunter